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mprovement of Left Ventricular Dysfunction and of
urvival Prognosis of Dilated Cardiomyopathy by Administrationa Mouse Modelo the Editor: Dilated cardiomyopathy (DCM) is a myocardial
isease with poor prognosis, characterized by progressive ventric-
lar dilation and systolic dysfunction. Underlying etiologies in-
lude idiopathic, viral (myocarditis), toxic agents and mitochon-
rial and metabolic disorders, but mutations in genes encoding
omponents of sarcomere, sarcolemma, cytoskeleton, or nuclear
nvelope—including lamin A/C (LMNA)—also cause DCM (1).
herefore, treatment and prevention of DCM are important
specially for the individuals who carry the disease-causing muta-
ion. We previously reported an animal model of DCM, Lmna
nock-in mouse carrying H222P mutation in homozygous state
LmnaH222P/H222P), which developed progressive contractile dys-
unction (2). To explore a therapeutic strategy for DCM, we
reated LmnaH222P/H222P mice with a pyridazinone derivative
alcium (Ca2) sensitizing agent SCH00013 (3). We found that
CH00013 ameliorated systolic dysfunction (Table 1), prolonged
ife expectancy, decreased cardiac interstitial fibrosis, and modu-
ated the expression of genes involved in cardiac remodeling (see
lso the Online Appendix for experimental details and additional
iscussion).
As a therapeutic strategy for heart failure, medication with
ngiotensin converting enzyme inhibitors, angiotensin II type I
eceptor blockers, and beta-blockers has been employed. Car-
iotonic agents could be useful for treatment of systolic dysfunc-
ion, because the agents augment cardiac contractility via increased
evel of cyclic adenosine-mono-phosphate (cAMP) in cardiomyo-
ytes, leading to an increase in intracellular Ca2 concentration.
lassical cardiotonic agents could provide short-term hemody-
amic benefits, but a long-term administration was correlated with
oor survival rates and often accompanied by adverse effects,
resumably due to the elevated Ca2 concentrations leading to
ardiotoxic and arrhythmogenic effects. However, Ca2 sensitizers
re novel cardiotonic agents that elicit a positive inotropic effect via
ncreasing Ca2 sensitivity of muscle contraction without increas-
ng the concentrations of cAMP and intracellular Ca2 (4).
We tested the effect of the long-term oral administration of a Ca2
ensitizer SCH00013 in DCM model LmnaH222P/H222P mice, be-
ause SCH00013 was reported to ameliorate the impaired contrac-
ility without superfluous expenditure of energy in the cardiac muscles
5). Body weight and water intake were not different betweenig. S1). Plasma concentrations of SCH00013 in the treated
mna/ and LmnaH222P/H222P male mice were 580.0  23.5
g/ml and 552.3  26.1 ng/ml, respectively, whereas those in
emale mice were 456.0  107.6 ng/ml and 411.5  43.8
g/ml, respectively (n  4 to 5 in each group). Untreated
mnaH222P/H222P male mice started to die at 4 months of age,
nd they all died by 11 months of age (Online Fig. S2). A 50%
urvival time was prolonged by the treatment (untreated mice
.90  0.26 months vs. treated mice 8.70  0.22 months, p 
.05), although a Kaplan-Meier analysis of the overall mortality
howed no statistical difference between them (p  0.14). By
ontrast, untreated LmnaH222P/H222P female mice died between 6
nd 13 months of age, and SCH00013 significantly improved
urvival prognosis, evidenced by the prolonged 50% survival time
9.80  0.26 months vs. 11.14  0.31 months, p  0.01) and
educed overall mortality (p  0.05, log-rank test).
Echocardiographic examination (Online Fig. S3) revealed that the
ntreated mice developed left ventricular dilation and contractile
ysfunction, evidenced by decreased left ventricular fractional short-
ning and left ventricular ejection fraction, which were overt after 2
onths of age in males and 4 months of age in females. The agent
CH00013 significantly improved left ventricular fractional shorten-
ng and left ventricular ejection fraction in males at 4 and 6 months of
ge and in females at 6, 8, and 10 months of age (Table 1). Systolic
lood pressure in LmnaH222P/H222P mice at 4 months of age was not
ignificantly modified by administration of SCH00013 for 2 months:
reated 124.0 3.4 mmHg versus untreated 121.0 2.2 mmHg in
ales, and treated 112.9 7.7 mmHg versus untreated 120.3 3.8
m Hg in females (n 8 and n 4 for treated and untreated mice,
espectively), demonstrating that SCH00013 improved the left ven-
ricular contractile dysfunction in LmnaH222P/H222P mice without
ffecting systolic blood pressure.
The LmnaH222P/H222P mice showed dilation of both ventricles
ith enlargement of atrial cavity often accompanied by atrial
hrombosis, which were prevented by the treatment (Online Fig.
4). Microscopic analyses demonstrated that the interstitial fibro-
is, degeneration, and necrosis of cardiomyocytes in the ventricles
f LmnaH222P/H222P mice were ameliorated by SCH00013 (On-
ine Fig. S4). Moreover, the increased collagen deposition in the
earts of LmnaH222P/H222P mice was significantly suppressed by
he treatment (Online Fig. S5).
Table 1 Echocardiographic Data for Untreated and SCH00013-Treated Lmna/ and LmnaH222P/H222P Mice
IVSd (mm) PWd (mm) LVM (mg) LVEDD (mm) LVESD (mm) LVFS (%) LVEF (%) Heart Rate (beats/min)
Data for male mice age 2, 4, 6, and 8 months
2 months of age
Untreated Lmna/ (n  15) 0.49 0.01 0.50 0.01 45.2 1.18 3.28 0.04 1.85 0.03 43.7 0.59 81.5 0.59 500 7
SCH Lmna/ (n  22) 0.50 0.01 0.54 0.01 46.7 1.36 3.21 0.03 1.80 0.03 43.9 0.75 81.7 0.76 523 9
Untreated LmnaH222P/H222P (n  21) 0.50 0.01 0.49 0.01 46.0 1.17 3.30 0.03 1.98 0.03* 39.6 0.93* 76.5 1.19* 524 7
SCH LmnaH222P/H222P (n  17) 0.49 0.02 0.51 0.02 46.0 1.76 3.28 0.03 1.92 0.02† 41.1 0.60† 78.4 0.77† 536 10
4 months of age
Untreated Lmna/ (n  12) 0.48 0.02 0.53 0.02 48.3 1.90 3.38 0.06 1.94 0.05 42.8 0.82 80.5 0.82 542 12
SCH Lmna/ (n  22) 0.52 0.01 0.54 0.01 51.7 1.36 3.38 0.03 1.95 0.03 42.5 0.68 80.0 0.72 526 7
Untreated LmnaH222P/H222P (n  21) 0.47 0.01 0.47 0.01* 55.4 2.05 3.80 0.07‡ 2.64 0.08‡ 30.9 1.07‡ 66.7 1.44‡ 560 10
SCH LmnaH222P/H222P (n  17) 0.49 0.01 0.50 0.01 55.8 2.09 3.69 0.06§ 2.33 0.06§ 37.0 0.92§¶ 72.9 1.97†# 543 7
6 months of age
Untreated Lmna/ (n  12) 0.49 0.01 0.53 0.02 56.1 2.10 3.64 0.04 2.10 0.03 42.3 0.46 79.9 0.63 532 9
SCH Lmna/ (n  21) 0.50 0.01 0.50 0.01 56.1 1.47 3.68 0.05 2.19 0.05 40.6 0.65 78.2 0.64 537 7
Untreated LmnaH222P/H222P (n  17) 0.43 0.01** 0.42 0.02‡ 57.5 2.28 4.34 0.12‡ 3.36 0.15‡ 23.0 1.29‡ 53.9 2.59‡ 516 18
SCH LmnaH222P/H222P (n  17) 0.46 0.01†† 0.43 0.01§ 58.8 2.30 4.10 0.10§ 3.01 0.12§# 27.0 1.29§# 60.6 2.08§# 533 7
8 months of age
Untreated Lmna/ (n  12) 0.50 0.01 0.49 0.02 54.1 2.57 3.62 0.07 2.07 0.06 43.0 0.64 80.8 0.62 535 11
SCH Lmna/ (n  21) 0.49 0.01 0.49 0.01 58.1 2.20 3.80 0.08 2.19 0.08 39.9 0.81 77.7 0.92 544 8
Untreated LmnaH222P/H222P (n  7) 0.37 0.01‡ 0.36 0.02‡ 52.0 5.27 4.37 0.12‡ 3.63 0.10‡ 15.9 0.88‡ 41.0 1.65‡ 566 20
SCH LmnaH222P/H222P (n  7) 0.38 0.01§ 0.37 0.01§ 54.4 3.65 4.38 0.15§ 3.50 0.16§ 19.5 0.79§ 48.3 3.08§ 552 11
Data for female mice age 2, 4, 6, 8, and 10 months
2 months of age
Untreated Lmna/ (n  7) 0.47 0.02 0.52 0.01 42.9 1.93 3.14 0.03 1.80 0.05 41.9 1.52 82.5 0.95 535 13
SCH Lmna/ (n  14) 0.49 0.01 0.51 0.01 40.9 1.38 3.10 0.02 1.77 0.03 42.7 0.80 80.5 0.84 521 10
Untreated LmnaH222P/H222P (n  18) 0.51 0.01 0.49 0.01 43.7 0.91 3.18 0.02 1.84 0.03 42.7 0.67 79.1 0.74 544 7
SCH LmnaH222P/H222P (n  14) 0.50 0.02 0.50 0.01 41.2 0.80 3.12 0.03 1.85 0.04 40.9 0.77 78.2 0.77 551 10
4 months of age
Untreated Lmna/ (n  7) 0.50 0.02 0.56 0.02 43.1 2.23 3.24 0.03 1.72 0.02 43.2 0.43 81.0 0.42 521 15
SCH Lmna/ (n  14) 0.50 0.01 0.52 0.02 47.1 1.35 3.28 0.04 1.88 0.03 42.3 0.73 80.3 0.71 530 16
Untreated LmnaH222P/H222P (n  18) 0.47 0.01 0.46 0.01‡ 45.9 1.27 3.48 0.05‡ 2.24 0.07‡ 36.0 0.84‡ 72.8 1.06‡ 553 8
SCH LmnaH222P/H222P (n  14) 0.49 0.01 0.50 0.02 46.5 2.04 3.32 0.04# 2.05 0.030††# 38.2 0.49§# 75.2 0.61†† 557 11
6 months of age
Untreated Lmna/ (n  7) 0.49 0.01 0.50 0.02 43.0 2.09 3.28 0.05 1.82 0.04 42.7 0.44 80.5 0.44 519 12
SCH Lmna/ (n  14) 0.49 0.01 0.49 0.01 45.8 1.91 3.33 0.04 1.87 0.03 43.8 0.39 81.2 0.35 521 8
Untreated LmnaH222P/H222P (n  16) 0.46 0.01 0.44 0.01* 46.5 1.38 3.66 0.07‡ 2.57 0.10‡ 30.0 1.43‡ 64.9 2.06‡ 555 9
SCH LmnaH222P/H222P (n  14) 0.46 0.02 0.45 0.01† 45.2 2.54 3.44 0.06# 2.23 0.07§ 35.4 1.05§ 71.6 1.22§ 558 7
8 months of age
Untreated Lmna/ (n  7) 0.47 0.03 0.49 0.02 42.4 1.67 3.24 0.05 1.80 0.03 44.4 0.76 82.3 0.84 510 16
SCH Lmna/ (n  14) 0.47 0.01 0.47 0.01 44.3 1.33 3.36 0.04 1.91 0.03 43.0 0.52 80.8 0.45 539 8
Untreated LmnaH222P/H222P (n  16) 0.40 0.01** 0.38 0.01‡ 47.4 1.41 3.99 0.07‡ 3.16 0.09‡ 21.2 1.15‡ 51.1 1.84‡ 572 9
SCH LmnaH222P/H222P (n  14) 0.42 0.01† 0.43 0.01† 48.8 2.60 3.80 0.13†† 2.72 0.17§# 29.3 2.03§ 63.2 3.20§ 542 9
10 months of age
Untreated Lmna/ (n  7) 0.49 0.01 0.47 0.01 44.3 1.45 3.32 0.04 1.88 0.03 43.6 0.58 81.4 0.38 529 13
SCH Lmna/ (n  13) 0.49 0.01 0.50 0.01 46.6 1.05 3.36 0.03 1.93 0.03 42.5 0.41 80.4 0.38 540 11
Untreated LmnaH222P/H222P (n  7) 0.35 0.02‡ 0.37 0.03** 52.1 4.09 4.40 0.11‡ 3.74 0.14‡ 15.1 1.72‡ 38.9 3.83‡ 506 28
SCH LmnaH222P/H222P (n  7) 0.42 0.02†† 0.43 0.02†† 54.4 4.51 4.05 0.16§ 3.11 0.21§# 23.6 2.36§# 54.4 4.21§# 547 21
Cardiac function was evaluated by transthoracic echocardiographic analyses of the left ventricle (LV). The left ventricular mass (LVM) and the percentage of left ventricular fractional shortening (LVFS) were calculated as follows: [(IVSd  PWd  EDD)3  EDD3]  1.055
and (LVEDD  LVESD)/LVEDD  100, respectively. *p  0.05, **p  0.01, and ‡p  0.001, versus age-matched untreated Lmna/ mice. †p  0.05, ††p  0.01, and §p  0.001, versus age-matched SCH00013-treated Lmna/ mice. #p  0.05, p  0.01, and
¶p  0.001, versus age-matched untreated LmnaH222P/H222P mice.
IVSd  interventricular septal wall thickness in diastole; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; LVESD  left ventricular end-systolic diameter; LVM  left ventricular mass; PWd  posterior wall thickness in diastole.
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April 6, 2010:1502–8We next investigated the gene expression in the hearts from
ntreated and treated Lmna/ and LmnaH222P/H222P female
ice, because the beneficial effect of SCH00013 was prominent
n female mice. In the hearts from untreated LmnaH222P/H222P
ice, Nppa, Nppb, Myh7, and Myl7 messenger ribonucleic acids
ere significantly increased, and the upregulation of Nppa and
yl7 was significantly reduced in the treated mice (Online Fig.
6). We also found increased messenger ribonucleic acid
xpression of proto-oncogene Fos and extracellular matrix
emodeling-related genes Tgfb1, Tgfb2, and Col1a2 in the
ntreated LmnaH222P/H222P mice, whereas these changes were
uppressed by the treatment (Online Fig. S6). Left ventricles
rom the untreated LmnaH222P/H222P mice showed 2.2-fold and
.7-fold increases of Nppa and Mlc2 proteins, respectively, as
ompared with the untreated Lmna/ mice, and the increased
xpression was suppressed by the treatment (Online Fig. S7). In
ddition, we investigated whether the apoptotic signal was
nduced by the Lmna mutation, because there is an association
mong apoptosis, cardiac myocyte drop-out, ventricular remod-
ling, and deterioration of systolic performance in various
xperimental models of heart failure. However, the number of
ransferase-mediated dUTP nick-end labeling–positive cells
as not increased in the hearts of LmnaH222P/H222P mice, and
estern blot analyses showed no or little expression of Fas-L or
as proteins, respectively, in the LmnaH222P/H222P mice (On-
ine Fig. S8). These results demonstrated that the apoptosis was
ot associated with the cardiac phenotypes in LmnaH222P/H222P
ice and suggested that loss of cardiomyocytes was caused by
ell death mechanisms other than the apoptosis.
The molecular mechanisms for the beneficial effect of
CH00013 remained unclear, but it might be related to the
hosphodiesterase III activity. This possibility is unlikely, however,
ecause SCH00013 inhibited the phosphodiesterase III activity at
uch higher concentration (IC50  64.9 mol/l) than the
oncentration at which it produced the positive inotropic effect
IC50  9.2 mol/l) in guinea pig hearts (3); and we showed that
he plasma concentration of SCH00013 in the LmnaH222P/H222P
ice ranged from 1 to 2 mol/l, although we did not measure the
oncentration in the hearts. By contrast, because the Ca2 sensi-
ivity of cardiac muscle contraction was not decreased in the
mnaH222P/H222P mice at 3 months of age (Online Fig. S9), the
a2 sensitizing effect might not play a major role at the early stage,
ut the Ca2 sensitizing effect of SCH00013 was enhanced in the
tretched muscles (5), raising a possibility that the Ca2 sensitivity in
he failed heart might be different. Although the molecular mecha-
isms should be clarified, our findings implied that the Ca2
ensitizer could be a plausible option for preventing disease progres-
ion of DCM.
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APPENDIX
or supplementary information and supplementary
gure legends, please see the online version of this article.
Letters to the Editor
Meta-Analysis of
emote Monitoring
f Heart Failure Patients
tructured disease management improves the prognosis of patients
ith chronic heart failure and has already been included in the
urrent treatment guidelines. Along with better medication and
ncreased use of defibrillators, planned periodic visits have also
ecome routine in clinical practice. Remote patient monitoring
RPM) is a different type of structured disease management.
lthough the RPM systems (telephone support, network care,
evice-assisted monitoring) and health care environments are
eterogeneous, the crucial difference from usual care is that RPM
nables daily contact with healthcare experts and thus facilitates
egular short-term evaluation of the disease status and early
ntervention. The elaborate meta-analysis by Klersy et al. (1)
ointed out considerable benefits to be gained from RPM in terms
